Shopping Cart
- Remove All
Your shopping cart is currently empty
Tenofovir alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $45 | In Stock | |
| 10 mg | $63 | In Stock | |
| 25 mg | $88 | In Stock | |
| 50 mg | $126 | In Stock | |
| 100 mg | $171 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock |
| Description | Tenofovir alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir. |
| In vitro | Tenofovir alafenamide has a potent anti-HIV activity with IC50 of 0.005 μM. [1] GS 7340 has a half-life of 90 min in human plasma and a half-life of 28.3 min in an MT-2 cell extract at 37°C. [2] the hepatic uptake of Tenofovir alafenamide isfacilitated by OATP1B1 and OATP1B3, respectively. Tenofovir alafenamide inhibits HBV reverse transcriptase after being converted to the pharmacologically active form, TFV-DP. [3] |
| In vivo | In male beagle dogs, GS 7340 (10 mg/kg, p.o.) results in an enhanced distribution to lymphatic tissue. [2] |
| Synonyms | GS-7340 |
| Molecular Weight | 476.47 |
| Formula | C21H29N6O5P |
| Cas No. | 379270-37-8 |
| Smiles | CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |
| Relative Density. | 1.39 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (115.43 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 88 mg/mL (184.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.2 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.